| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 10/02/2001 | US6297217 Boronic ester and acid compounds, synthesis and uses |
| 10/02/2001 | US6297049 Methods and compositions for ameliorating the symptoms of sepsis |
| 10/02/2001 | US6297039 Amps from Streptococcus pneumoniae |
| 10/02/2001 | US6297036 YAK-1 related serine/threonine protein kinase-HTLAR33 |
| 10/02/2001 | US6297022 Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 |
| 10/02/2001 | US6297003 Methods for the detection of a novel hepatitis C virus (HCV) terminal 3′ noncoding region |
| 10/02/2001 | US6296858 Cosmetic composition comprising an aqueous dispersion of film-forming polymer particles containing 1,2-pentanediol |
| 10/02/2001 | US6296854 Live attenuated Venezuelan Equire encephalitis vaccine |
| 10/02/2001 | US6296853 For therapy of animal having a papilloma viral infection |
| 10/02/2001 | US6296851 For screening antibiotics |
| 10/02/2001 | US6296844 Administering asialointerferon-.beta.. to mammal for therapy of viral hepatitis |
| 10/02/2001 | CA2078000C Neutrophil stimulating peptides |
| 09/30/2001 | CA2310365A1 Passive and active protection against mycobacterial infections |
| 09/27/2001 | WO2001071358A1 Method of screening for inhibitors of osteopontin |
| 09/27/2001 | WO2001071346A2 Binding compounds for cc chemokine receptor 5 and methods for identifying them |
| 09/27/2001 | WO2001071343A1 Methods for screening and identifying pathogen virulence factors |
| 09/27/2001 | WO2001071309A2 Methods and reagents for regulation of cellular responses in biological systems |
| 09/27/2001 | WO2001071007A2 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF |
| 09/27/2001 | WO2001071005A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | WO2001071004A2 Proteases |
| 09/27/2001 | WO2001070984A2 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 09/27/2001 | WO2001070955A2 Identification of essential genes in prokaryotes |
| 09/27/2001 | WO2001070951A2 Agent for the diagnosis and therapy of viral diseases |
| 09/27/2001 | WO2001070941A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | WO2001070807A2 G-protein associated molecules |
| 09/27/2001 | WO2001070776A2 Nimr compositions and their methods of use |
| 09/27/2001 | WO2001070772A2 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid |
| 09/27/2001 | WO2001070769A1 Peptide derivative |
| 09/27/2001 | WO2001070768A2 Receptor-binding compounds and method for identifying them |
| 09/27/2001 | WO2001070766A2 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | WO2001070765A1 Receptor-binding compounds and methods for identifying them |
| 09/27/2001 | WO2001070742A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
| 09/27/2001 | WO2001070738A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 09/27/2001 | WO2001070734A2 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | WO2001070729A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 09/27/2001 | WO2001070723A1 Benzothiophene derivatives and medicinal use thereof |
| 09/27/2001 | WO2001070706A2 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents |
| 09/27/2001 | WO2001070695A1 Pyridine derivatives as inhibitors of p38 |
| 09/27/2001 | WO2001070694A1 Amorphous torasemide modification |
| 09/27/2001 | WO2001070693A2 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 09/27/2001 | WO2001070690A1 Heterocyclic side chain containing metalloprotease inhibitors |
| 09/27/2001 | WO2001070674A1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 09/27/2001 | WO2001070673A2 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 09/27/2001 | WO2001070668A2 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 09/27/2001 | WO2001070663A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | WO2001070267A1 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use |
| 09/27/2001 | WO2001070262A2 A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
| 09/27/2001 | WO2001070247A2 Salmonella vaccine materials and methods |
| 09/27/2001 | WO2001070246A1 Use of lactic acid bacterium for the treatment of peritonitis |
| 09/27/2001 | WO2001070232A1 Protease inhibitors |
| 09/27/2001 | WO2001070225A2 Oxazolidinone tablet formulation |
| 09/27/2001 | WO2001070219A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 09/27/2001 | WO2001070216A2 Diphenyl ketoaldehyde derivatives with anti-hiv activity |
| 09/27/2001 | WO2001070215A1 Bactericidal preparation |
| 09/27/2001 | WO2001070213A2 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure |
| 09/27/2001 | WO2001070209A2 Mono- and disaccharides for the treatment of nitric oxide related disorders |
| 09/27/2001 | WO2001070208A2 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate |
| 09/27/2001 | WO2001070203A2 Agent for treating hepatitis c containing ukrain |
| 09/27/2001 | WO2001070200A1 Pharmaceutical composition for administration to mucosal surfaces |
| 09/27/2001 | WO2001070199A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 09/27/2001 | WO2001070173A2 Immunokine composition and method |
| 09/27/2001 | WO2001070172A2 Solid, water-dispersible, oral pharmaceutical form comprising rifampicin, isoniazid and pyridoxine hydrochloride, method for obtaining and presenting said pharmaceutical form |
| 09/27/2001 | WO2001070170A1 Container for linezolid intravenous solution |
| 09/27/2001 | WO2001070032A1 Recombinant parainfluenza virus expression systems and vaccines |
| 09/27/2001 | WO2001032663A3 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 09/27/2001 | WO2001032654A3 Novel heterocyclic compounds and their use as medicines |
| 09/27/2001 | WO2001030754A3 Micro-cluster liquids and methods of making and using them |
| 09/27/2001 | WO2001021207A3 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 09/27/2001 | WO2001020013A3 Viral replicons and viruses dependent on inducing agents |
| 09/27/2001 | WO2001019973A3 Nicotinic acetylcholine receptor: alpha10 subunit |
| 09/27/2001 | WO2001019829A3 Pyrazolopyrimidines as therapeutic agents |
| 09/27/2001 | WO2001017551A3 Combined vaccine compositions |
| 09/27/2001 | WO2001016170A3 Card proteins involved in cell death regulation |
| 09/27/2001 | WO2001015684A3 Antimycotic drug |
| 09/27/2001 | WO2001014576B1 Process and intermediates for the preparation of isoxazolecaroxamides and analogues |
| 09/27/2001 | WO2001012127B1 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 09/27/2001 | WO2001009178A3 Human chaperone proteins |
| 09/27/2001 | WO2001004134A3 Novel esters derived from nucleosides, preparation methods and pharmaceutical compositions containing them |
| 09/27/2001 | WO2000078275A3 Antibacterial compositions |
| 09/27/2001 | WO2000061541A3 Pharmaceutical compounds |
| 09/27/2001 | WO2000041707A3 USE OF $i(LACTOBACILLUS SALIVARIUS) |
| 09/27/2001 | US20010025108 Thrombosis diseases |
| 09/27/2001 | US20010025104 Amination of clavulanic acid |
| 09/27/2001 | US20010025058 Therapy for fungus infections |
| 09/27/2001 | US20010025044 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli |
| 09/27/2001 | US20010025033 Uracil substituted at 5-position by C2-4 alkynyl used as inactivator of uracil reductase enzyme |
| 09/27/2001 | US20010025029 Novel stromelysin inhibitors |
| 09/27/2001 | US20010024817 Viral nucleotide sequences |
| 09/27/2001 | US20010024664 Alzheimer's diseases; central nervous system disorders; antiinflammatory agent; solvent extraction from plants |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | US20010024653 Recombinant mycobacterium strain containing in its chromosome or on a plasmid a counterpart to a gene (which has been deactivated) in the wild type mycobacterium coding for a protein necessary for biosynthesis of a purine or pyrimidine |
| 09/27/2001 | US20010024642 A chewing gum that includes a gum center and a coating that substantially surrounds the center, comprises at least 50% by weight of chewing gum, the coating includes medicine; chewing the gum, causes the drug release, in patients buccal cavity |
| 09/27/2001 | US20010023664 Chicken anaemia viruses of low pathogenicity |
| 09/27/2001 | DE10015413A1 Composition for treating and diagnosing viral infections, caused by adenovirus, comprises an agent that modifies function of YB-1 protein, and YB-1 specific antibodies |
| 09/27/2001 | DE10012370A1 Use of oil-in-water emulsion as vaccine adjuvant, particularly for influenza and pneumococcal vaccines, administered at different site from the vaccine |
| 09/27/2001 | DE10012120A1 New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2404260A1 Identification of essential genes in prokaryotes |
| 09/27/2001 | CA2404206A1 Protease inhibitors |
| 09/27/2001 | CA2404139A1 Binding compounds and methods for identifying binding compounds |